Por favor, use este identificador para citar o enlazar este Item:http://hdl.handle.net/20.500.12105/16472
Título
Prognosis of Transthyretin Cardiac Amyloidosis Without Heart Failure Symptoms.
Autor(es)
Gonzalez-Lopez, Esther CNIC | Escobar-Lopez, Luis | Obici, Laura | Saturi, Giulia | Bezard, Mélanie | Saith, Sunil E | AbouEzzeddine, Omar F | Mussinelli, Roberta | Gagliardi, Christian | Kharoubi, Mounira | Griffin, Jan M | Dispenzieri, Angela | Vilches, Silvia | Perlini, Stefano | Longhi, Simone | Oghina, Silvia | Rivas, Adrian | Grogan, Martha | Maurer, Mathew S | Damy, Thibaud | Palladini, Giovanni | Rapezzi, Claudio | Garcia-Pavia, Pablo CNIC
Fecha de publicación
2022-11
Cita
JACC CardioOncol. 2022 Nov 15;4(4):442-454.
Idioma
Inglés
Tipo de documento
journal article
Resumen
BACKGROUND
Transthyretin amyloid cardiomyopathy (ATTR-CM) is increasingly recognized as a treatable cause of heart failure (HF). Advances in diagnosis and therapy have increased the number of patients diagnosed at early stages, but prognostic data on patients without HF symptoms are lacking. Moreover, it is unknown whether asymptomatic patients benefit from early initiation of transthyretin (TTR) stabilizers.
OBJECTIVES
The aim of this study was to describe the natural history and prognosis of ATTR-CM in patients without HF symptoms.
METHODS
Clinical characteristics and outcomes of patients with ATTR-CM without HF symptoms were retrospectively collected at 6 international amyloidosis centers.
RESULTS
A total of 118 patients (78.8% men, median age 66 years [IQR: 53.8-75 years], 68 [57.6%] with variant transthyretin amyloidosis, mean left ventricular ejection fraction 60.5% ± 9.9%, mean left ventricular wall thickness 15.4 ± 3.1 mm, and 53 [45%] treated with TTR stabilizers at baseline or during follow-up) were included. During a median follow-up period of 3.7 years (IQR: 1-6 years), 38 patients developed HF symptoms (23 New York Heart Association functional class II and 14 functional class III or IV), 32 died, and 2 required cardiac transplantation. Additionally, 20 patients received pacemakers, 13 developed AF, and 1 had a stroke. Overall survival was 96.5% (95% CI: 91%-99%), 90.4% (95% CI: 82%-95%), and 82% (95% CI: 71%-89%) at 1, 3, and 5 years, respectively. Treatment with TTR stabilizers was associated with improved survival (HR: 0.31; 95% CI: 0.12-0.82; P = 0.019) and remained significant after adjusting for sex, age, ATTR-CM type, and estimated glomerular filtration rate (HR: 0.18; 95% CI: 0.06-0.55; P = 0.002).
CONCLUSIONS
After a median follow-up period of 3.7 years, 1 in 3 patients with asymptomatic ATTR-CM developed HF symptoms, and nearly as many died or required cardiac transplantation. Treatment with TTR stabilizers was associated with improved prognosis.
Versión en línea
DOI
Aparece en las colecciones
Ficheros en el ítem
![Acceso Abierto Acceso Abierto](/themes/Mirage2/images/openAccess.png)
- Nombre:
- Prognosis of Transthyretin_JACC ...
- Tamaño:
- 1.146Mb
- Formato:
- Descripción:
- Artículo